chr9-127612405-T-G
Position:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1PM2PP5_Moderate
The NM_003165.6(STXBP1):c.2T>G(p.Met1?) variant causes a start lost change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★).
Frequency
Genomes: not found (cov: 30)
Consequence
STXBP1
NM_003165.6 start_lost
NM_003165.6 start_lost
Scores
3
7
6
Clinical Significance
Conservation
PhyloP100: 0.0360
Genes affected
STXBP1 (HGNC:11444): (syntaxin binding protein 1) This gene encodes a syntaxin-binding protein. The encoded protein appears to play a role in release of neurotransmitters via regulation of syntaxin, a transmembrane attachment protein receptor. Mutations in this gene have been associated with infantile epileptic encephalopathy-4. Alternatively spliced transcript variants have been described. [provided by RefSeq, Feb 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Start lost variant, no new inframe start found.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 9-127612405-T-G is Pathogenic according to our data. Variant chr9-127612405-T-G is described in ClinVar as [Pathogenic]. Clinvar id is 2019337.Status of the report is criteria_provided_single_submitter, 1 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
STXBP1 | NM_003165.6 | c.2T>G | p.Met1? | start_lost | 1/20 | ENST00000373302.8 | |
STXBP1 | NM_001032221.6 | c.2T>G | p.Met1? | start_lost | 1/19 | ENST00000373299.5 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
STXBP1 | ENST00000373302.8 | c.2T>G | p.Met1? | start_lost | 1/20 | 1 | NM_003165.6 | P3 | |
STXBP1 | ENST00000373299.5 | c.2T>G | p.Met1? | start_lost | 1/19 | 1 | NM_001032221.6 | A1 |
Frequencies
GnomAD3 genomes Cov.: 30
GnomAD3 genomes
Cov.:
30
GnomAD4 exome Cov.: 31
GnomAD4 exome
Cov.:
31
GnomAD4 genome Cov.: 30
GnomAD4 genome
Cov.:
30
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
Early infantile epileptic encephalopathy with suppression bursts Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 23, 2022 | Disruption of the initiator codon has been observed in individual(s) with epileptic encephalopathy (PMID: 34489640). In at least one individual the variant was observed to be de novo. For these reasons, this variant has been classified as Pathogenic. This variant is not present in population databases (gnomAD no frequency). This sequence change affects the initiator methionine of the STXBP1 mRNA. The next in-frame methionine is located at codon 15. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Uncertain
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
.;T;.;T;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
D
LIST_S2
Uncertain
D;D;D;D;.
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D
MetaSVM
Uncertain
T
MutationTaster
Benign
D;D
PROVEAN
Benign
N;.;.;N;.
REVEL
Uncertain
Sift
Uncertain
D;.;.;D;.
Sift4G
Uncertain
D;.;.;D;.
Polyphen
D;.;.;D;.
Vest4
MutPred
Gain of methylation at M1 (P = 0.0174);Gain of methylation at M1 (P = 0.0174);Gain of methylation at M1 (P = 0.0174);Gain of methylation at M1 (P = 0.0174);Gain of methylation at M1 (P = 0.0174);
MVP
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.